Floatz logo

Heptanoin, Tri-

Huntington Disease

Institut National de la Santé Et de la Recherche Médicale, FranceSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Huntington Disease cohort.

Asset / SponsorPhaseRating
Deutetrabenazine
Teva Branded Pharmaceutical Products R&D LLC
Phase 4BBB
Tetrabenazine
William Ondo, MD
Phase 4BBB
Tominersen
Hoffmann-La Roche
Phase 3BBB
Latrepirdine
Medivation, Inc.
Phase 3BB
Pridopidine
Prilenia
Phase 3BB

View all 50 →

Same molecule, other indications

Heptanoin, Tri- is also rated in:

GLUT1 deficiency syndromeDormant
BB
Indicative · Phase 2
69 / 100
View asset →
encephalopathy due to GLUT1 deficiencyDormant
BB
Indicative · Phase 2
64 / 100
View asset →
glucose metabolism diseaseDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →